Chiropractors in Kc, MO Accepting Medicare
1 Chiropractors found. Showing 1 - 1
 Dr. Sam Elashkar, DC, PHD Chiropractor - Nutrition Medicare: Not Enrolled in Medicare Practice Location: 6301 Rockhill Rd.,, Emmanuel Chiropractic Clinic, Suite 105, Kc, MO 64131 Phone: 913-954-9380 Fax: 816-523-4623 |
News Archive
Researchers pinpoint circuit in the brain responsible for encoding decision-making
Researchers at The Johns Hopkins University have pinpointed a circuit in the brain responsible for encoding decision-making behavior, a circuit that - if damaged - appears to prevent a person from altering that behavior when circumstances change.
Plastic baby feeding bottles shed microplastic particles, say researchers
This new study from researchers at Environmental Engineering, Trinity College Dublin, and the Medical University of Vienna shows that an average of 1 million microplastic particles per day are consumed by infants drinking from these feeding bottles. The study results are published in the latest issue of the journal Nature Food.
State legislature directs UC system to allocate $15M annually to UCR medical school
A budget compromise worked out and signed today by Gov. Jerry Brown means that UC Riverside's School of Medicine will receive full and continuous funding of $15 million per year - long-sought assistance that enables the school to flourish and greatly facilitates its ongoing accreditation.
FDA approves pediatric use of Protopam Chloride
The U.S. Food and Drug Administration has approved the pediatric use of Protopam Chloride (pralidoxime chloride), a drug used to treat poisoning by organophosphate pesticides and chemicals (e.g., nerve agents). The drug is approved to be administered either by intravenous (IV) or intramuscular (IM) injections.
Intellect Neurosciences receives Notice of Allowance from Israeli patent office for OXIGON drug candidate
Intellect Neurosciences, Inc announced it has received a Notice of Allowance from the Israeli Patent and Trademark Office for a new patent related to the Company's clinical-stage drug candidate OX1 (OXIGON), which has disease-modifying potential for Alzheimer's and other neurodegenerative disorders.
› Verified 4 days ago